Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients.

The COVID-19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID-19-associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS-CoV-2 vaccination may help reduce the morbidity and mortality of COVID-19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS-CoV-2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA-1273 (Moderna)] and an adenovirus vector-based vaccine [Ad26.COV2.S (Johnson and Johnson)].